Status:

RECRUITING

Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute Low Back Pain

Lead Sponsor:

Insel Gruppe AG, University Hospital Bern

Conditions:

Low Back Pain

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The EMISI trial is a randomized, double blind, controlled trial (RCT) using a factorial design in patients with a new low back pain episode. The study aims to assess (A) whether metamizole, a non-opio...

Detailed Description

Purpose Low back pain (LBP) is among the top three most common diseases worldwide resulting in a life with pain-related disability. In patients with persistent LBP over 3 months, the risk for chronic ...

Eligibility Criteria

Inclusion

  • Informed consent as documented by signature
  • Age 18 years or older
  • Seeking care for new onset of non-specific or specific LBP (pain duration of less than 12 weeks LBP prior to the baseline visit)
  • The GP plans to prescribe a non-opioid pain medication for pain control

Exclusion

  • Presence of red flags (serious neurological deficit requiring surgery, infection, vertebral fracture)
  • Active malignancy and / or history of a (previous) hematologic disorder (anemia (hemoglobin \< 10.0 g/L), neutropenia or agranulocytosis, thrombocytopenia),
  • Known contraindications against the study medications: heart failure (NYHA III-IV), liver failure (liver cirrhosis, ascites), renal insufficiency (estimated glomerular filtration rate (eGFR) \< 60 ml/min/1,73 m2) or previous acute kidney injury (AKI stage 2 according to the KDIGO definition), previous gastrointestinal ulcer, inflammatory bowel disease.
  • Immune deficiency or under immunosuppressant treatment
  • Current use of opioids
  • Known intolerance to the study medication (i.e. previous acute allergic reaction to the study medication)
  • Patients unable or unwilling to follow instructions or do not speak and are unable to read / understand German
  • Patients unable to provide informed consent themselves
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc.
  • Participation in another study within the 30 days preceding the randomization and during the present study or previous enrolment into the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Pregnancy: In women in the child bearing age a negative pregnancy test (urine or blood test as available in the primary care practice) before inclusion is required. Women who are not willing to use safe contraception (condom or birth control pill) during the course of the trial, intention to become pregnant during the trial, pregnancy, or breast feeding

Key Trial Info

Start Date :

December 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT04111315

Start Date

December 15 2019

End Date

December 31 2025

Last Update

February 7 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Bern

Bern, Switzerland, 3010